 |
Partners' Directory |
| Home Search Join the Partnership Login | |
| Contact | General | Specializations in Countries | Contribution to the Global Plan | Declaration |
View this partner's profile
Organization Contact Information | |
| Name: | Mylan |
| Street 1: | 405 Lexington Ave |
| Street 2: | Floor 52 |
| City: | New York |
| Province: | |
| Post Code: | New York |
| Country: | United States of America |
| Phone: | +1 9172622950 |
| Organization Email: | kellen.thomas@mylan.com |
| Web Site: | http://www.mylan.com/ |
| Other Online Presence: | |
|
|
||||||||||||||||||||||||||||
General Information | |
| Board Constituency: | None |
| Is your organization legally registered in your country: | Yes |
| If yes, please enter your registration number: | Unclear what is meant by "registration number" |
| Organization Type - Primary: | Private Sector |
| Organization Type - Secondary: | Health |
| Organization Description: | |
| Mylan is a global pharmaceutical company committed to setting new standards in healthcare and providing 7 billion people access to high quality medicine. We offer a growing portfolio of more than 7,500 products, including prescription generic, branded generic, brand-name and biosimilar drugs, as well as over-the-counter (OTC) remedies. We market our products in more than 165 countries and territories. Currently, Mylan is the largest supplier – by volume – of antiretroviral drugs, supplying approximately 40% of HIV patients on treatment in low-and middle-income countries. In addition, we’ve been committed to ensuring that these products are affordable and accessible to those who need them most. We plan on using this vast infrastructure to successfully deliver on a comprehensive portfolio of tuberculosis drugs so that we can improve treatment rates and help support substantial reductions in new TB cases. |
|
| Do you know about the UNHLM declaration: | Yes |
Specializations / Areas of Work | |
|
Civil Society and Community Engagement Engaging political leaders and ensuring inclusive leadership Provision of drugs, diagnostics and commodities Research and Development |
Other Organization Information | |
| Total number of staff in your organization: | 100 + |
| Number of full-time staff who are directly involved with TB: | 11 - 25 |
| Number of part-time staff who are directly involved with TB: | 0 |
| Number of volunteers who are directly involved with TB: | 0 |
| How did you hear about the Stop TB Partnership: | Other partners |
| If you were informed or referred by another partner of the Stop TB Partnership please tell us who: | Private Sector Consortium |
| Why do you wish join the Stop TB Partnership: | Information on developments within the TB world |
| Are you a member of a Stop TB national partnership: | No |
| Are you in contact with your national TB programme: | Yes |
| Please tell us how your organization is contributing to your country's national TB control plan: | |
| We are actively supporting National TB Program's around the world through the provision of tubeculosis drugs (e.g. delamanid). We plan on ramping up these efforts, particularly in the developing world, given the recent US FDA approval of PRetomanid | |
Geographical Reach | |
| Which country is your headquarters located in: | United States of America |
| Which countries do you do operate in: (This includes countries you are conducting activities in) |
Afghanistan Albania Algeria Andorra Angola Antigua and Barbuda Argentina Armenia Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Central African Republic Chad Chile China Colombia Comoros Congo Cook Islands Costa Rica Cote d'Ivoire Croatia Cuba Cyprus Czech Republic Democratic People's Republic of Korea Democratic Republic of the Congo Democratic Republic of Timor-Leste Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Eswatini Ethiopia Fiji Finland France Gabon Gambia Georgia Germany Ghana Greece Grenada Guatemala Guinea Guinea-Bissau Guyana Haiti Honduras Hungary Iceland India Indonesia Iran (Islamic Republic of) Iraq Ireland Israel Italy Jamaica Japan Jordan Kazakhstan Kenya Kiribati Kuwait Kyrgyzstan Lao People's Democratic Republic Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Lithuania Luxembourg Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Mauritania Mauritius Mexico Micronesia (Federated States of) Monaco Mongolia Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Zealand Nicaragua Niger Nigeria Niue Norway Oman Pakistan Palau Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Qatar Republic of Korea Republic of Moldova Republic of Montenegro Republic of Serbia Romania Russian Federation Rwanda Saint Kitts and Nevis Saint Lucia Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Sudan Spain Sri Lanka Sudan Suriname Sweden Switzerland Syrian Arab Republic Tajikistan Thailand The Former Yugoslav Rep of Macedonia Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Tuvalu Uganda Ukraine United Arab Emirates United Kingdom of Great Britain and Northern Ireland United Republic of Tanzania United States of America Uruguay Uzbekistan Vanuatu Venezuela Viet Nam Yemen Zambia Zimbabwe |
Contribution | |
| Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below: | |
|
Drug-Resistant TB: Mylan is currently commercializing several drugs which are used for the treatment of drug-resistant TB. Per our latest announcement with the TB Alliance, in addition to our agreement with Otsuka, Mylan will be the first generic manufacturer of Pretomanid, Bedaquiline (for drug sensitive TB) and Delamanid. We plan on commercializing our full TB portfolio in high-burden drug-resistant countries, actively working with donors/governments/NGOs in scaling-up national programs, and continually demonstrating our commitment to affordability and access. TB-HIV: Currently, Mylan is the largest supplier – by volume – of antiretroviral drugs, supplying approximately 40% of HIV patients on treatment in low-and middle-income countries. This intersects with our commitment to TB and reflects our continued support of engaging in proactive and thoughtful R&D, affordability/access, and ensuring that TB/HIV coinfected patients are able to receive the best possible treatment. We plan on commercializing our TB drugs in countries with high HIV/TB burden and look forward to working with stakeholders to ensure access to this population. New TB Drugs: As of April 2019, Mylan and TB Alliance announced a global collaboration to make the experimental drug pretomanid accessible for use in two investigational drug regimens for pulmonary tuberculosis (BPaL and BPaMZ). Both regimens should offer substantial benefits, including a substantially shortened treatment duration. As part of this collaboration, Mylan is committed to supporting additional clinical work to develop the necessary evidence base and developing pediatric formulations of the product. In addition to Pretomanid, Mylan entered into a license agreement with Otsuka to commercialize Delamanid in select low- and middle-income countries. We are now working with Otsuka to manufacture the product in-house, which should result in substantial cost savings the long-term. Research: While Mylan has yet to develop a final research plan, Mylan is committed to supporting and engaging in operational research, particularly as it relates to Pretomanid introduction and data development in national TB programs outside of the United States. Mylan is diligently working with stakeholders and is looking for any engagement / suggestions on the most impactful approach moving forward. |
|
Declaration | |
| Declaration of interests: Mylan is a pharmaceutical company that is currently manufacturing a number of medicines for Tuberculosis. Like any pharmaceutical company, we have a vested financial interest in successfully commercializing our product portfolio. | |
| Application date: | September 17, 2019 |
| Last updated: | September 17, 2019 |